Altered prostaglandin E1 dosage during extracorporeal membrane oxygenation in a newborn with ductal-dependent congenital heart disease

Pediatr Cardiol. 2006 May-Jun;27(3):360-3. doi: 10.1007/s00246-005-1189-8.

Abstract

We describe a neonate with ductal-dependent congenital heart disease on extracorporeal membrane oxygenation (ECMO) for persistent pulmonary hypertension, who required markedly high doses of prostaglandin E1 (PGE1) to maintain patency of the ductus arteriosus: The effects of ECMO on the pharmacokinetics of PGE1 are discussed.

Publication types

  • Case Reports

MeSH terms

  • Alprostadil / administration & dosage*
  • Alprostadil / metabolism
  • Ductus Arteriosus, Patent / diagnostic imaging
  • Extracorporeal Membrane Oxygenation*
  • Female
  • Heart Defects, Congenital / diagnostic imaging
  • Heart Defects, Congenital / therapy*
  • Humans
  • Hypertension, Pulmonary / congenital
  • Hypertension, Pulmonary / therapy
  • Infant, Newborn
  • Meconium Aspiration Syndrome / therapy
  • Pulmonary Valve Stenosis / therapy*
  • Ultrasonography
  • Vasodilator Agents / administration & dosage*
  • Vasodilator Agents / metabolism

Substances

  • Vasodilator Agents
  • Alprostadil